DOTmed.com, March 23, 2016. Diana Zuckerman, president of the National Center for Health Research, wrote on behalf of the watchdog group that it was “concerned that the focus of these bills is on getting medical products to market more quickly, instead of making sure they are safe and effective.”
Read More »News That Quotes Us & Our Work
We are often quoted in major newspapers and magazines, and on well-respected TV shows, radio programs, and websites where we share our opinion on issues that matter to you and your health. Stay up to date on health news and our take on it by reading the articles in this section.
US Device Industry and FDA “Colluded” on Legislation to Weaken Regulatory Oversight
The BMJ, December 17, 2005. Dr. Diana Zuckerman from The National Center for Health Research shared, “There’s a world of difference between talking about approval standards in general and crafting specific legislative language. It is outrageous that FDA officials and regulated industry are sitting down to craft legislative language to give to congressional staff.”
Read More »Senate Committee Approves Legislation to Speed Approval of Medical Devices
The Wall Street Journal, March 9, 2016. Patient-safety advocates, including the National Center for Health Research, warn that the bills would weaken the FDA’s ability to ensure devices’ safety.
Read More »Senate HELP Innovate-A-Palooza
Politico, March 9, 2016. The National Center for Health Research is concerned that the Innovation Act, including the MEDTECH bill, will endanger patient safety by reducing FDA oversight.
Read More »PhRMA: Easing Speech Limits Could Reduce Need for Subgroups in Trials
InsideHealthPolicy.com, March 7, 2016. While minority, patient and consumer groups pushed for more diversity in the clinical trial phase, Jocelyn Ulrich director of scientific and regulatory affairs at the Pharmaceutical Research and Manufacturers of America (PhRMA), said matching demographic subgroups based on sex, age and race, specifically the African American and Hispanic populations, to disease prevalence would extend phase III clinical trials by 20 months or longer.
Read More »